We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

15 hedge funds and large institutions have $1.33M invested in Moleculin Biotech in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.87% less ownership

Funds ownership: 10.57% → 7.7% (-2.9%)

17% less funds holding

Funds holding: 18 → 15 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

85% less capital inflows, than outflows

Capital inflows: $100K | Capital outflows: $653K

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$36.9K
2
Millennium Management
Millennium Management
New York
+$21.1K
3
P.J. Schmidt Investment Management (PJS)
P.J. Schmidt Investment Management (PJS)
Wisconsin
+$21.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
Sio Capital Management
Sio Capital Management
New York
-$501K
2
BlackRock
BlackRock
New York
-$42.2K
3
Sigma Planning Corp
Sigma Planning Corp
Michigan
-$31.7K
4
Citadel Advisors
Citadel Advisors
Florida
-$30.6K
5
Virtu Financial
Virtu Financial
New York
-$16K

MBRX Hedge Fund Activity: Q2 2023 in Review

15 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2023, worth a combined $1.33M — down 54% from $2.91M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MBRX and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Squarepoint, adding an estimated $36.9K. The largest seller was Sio Capital Management, cutting an estimated $501K.

  • 15 institutional investors held Moleculin Biotech (MBRX) as of Q2 2023, down from 18 in Q1 2023.
  • Funds reported $1.33M of Moleculin Biotech stock for Q2 2023, down 54% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q2 2023 and 5 closed out, a net change of -3 holders.
  • The largest Moleculin Biotech buyer in Q2 2023 was Squarepoint, an estimated $36.9K added.
  • The largest Moleculin Biotech seller in Q2 2023 was Sio Capital Management, an estimated $501K sold.

Based on aggregated 13F filings for Q2 2023.